The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
The biology of progesterone receptor in the normal mammary gland and in breast cancer
Open accessAbstract
This paper reviews work on progesterone and the progesterone receptor (PR) in the mouse mammary gland that has been used extensively as an experimental model. Studies have led to the concept that progesterone controls proliferation and morphogenesis of the luminal epithelium in a tightly orchestrated manner at distinct stages of development by paracrine signaling pathways, including receptor of activated nuclear factor κ ligand (RANKL) as a major paracrine factor. Progesterone also drives expansion of stem cells by paracrine signals to generate progenitors required for alveologenesis. During mid-to-late pregnancy, progesterone has another role to suppress secretory activation until parturition mediated in part by crosstalk between PR and prolactin/Stat5 signaling to inhibit induction of milk protein gene expression, and by inhibiting tight junction closure. In models of hormone-dependent mouse mammary tumors, the progesterone/PR signaling axis enhances pre-neoplastic progression by a switch from a paracrine to an autocrine mode of proliferation and dysregulation of the RANKL signaling pathway. Limited experiments with normal human breast show that progesterone/PR signaling also stimulates epithelial cell proliferation by a paracrine mechanism; however, the signaling pathways and whether RANKL is a major mediator remains unknown. Work with human breast cancer cell lines, patient tumor samples and clinical studies indicates that progesterone is a risk factor for breast cancer and that alteration in progesterone/PR signaling pathways contributes to early stage human breast cancer progression. However, loss of PR expression in primary tumors is associated with a less differentiated more invasive phenotype and worse prognosis, suggesting that PR may limit later stages of tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889 · cited 7×
“Two clinical studies, the Women’s Health Initiative (WHI) and the Million Women study, have demonstrated that the progestin MPA is a risk factor for breast cancer in postmenopausal women receiving hormone replacement therapy (HRT) (Beral, 2003; Lee et al., 2006; Ross et al., 2000; Rossouw et al., 2002).”
BackgroundInfluentialThe basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964 · cited 14×
“Transgenic mice overexpressing PR-A develop abnormally and exhibit hyperplasias and disorganization of epithelial-basement membrane interactions (Shyamala et al., 1998).”
BackgroundInfluentialOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“However, it is expressed in a wide variety of other tissues and was subsequently shown in RANKL deficient mice to be required for cellular proliferation, survival and alveologenesis of mammary gland during pregnancy (Dougall et al., 1999; Fata et al., 2000; Kong et al., 1999).”
BackgroundGeneration of a functional mammary gland from a single stem cell
Shackleton, M., Vaillant, F., Simpson, K. J., Stingl, J., Smyth, G. K., Asselin-Labat, M.-L., Wu, L., Lindeman, G. J., & Visvader, J. E. (2006) · Nature · doi:10.1038/nature04372 · Cited by 2,005 · cited 2×
“Limited numbers of cells enriched for these markers have the ability in serial transplantations to repopulate a complete mammary gland containing both luminal and myoepithelial cells as well as lobuloalveolar structures during pregnancy (Shackleton et al., 2006; Stingl et al., 2006; Vaillant et al., 2007).”
BackgroundRANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin
Ross, R. K. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.4.328 · Cited by 877
Control of mammary stem cell function by steroid hormone signalling
Asselin-Labat, M.-L., Vaillant, F., Sheridan, J. M., Pal, B., Wu, D., Simpson, E. R., Yasuda, H., Smyth, G. K., Martin, T. J., Lindeman, G. J., et al. (2010) · Nature · doi:10.1038/nature09027 · Cited by 693 · cited 7×
“…P4 can regulate MaSCs, administration of P4 in intact adult mice increased the population of MaSCs and ovariectomy reduced the total number of repopulating cells in the mammary gland and diminished ductal outgrowths in transplantation experiments (Asselin-Labat et al., 2010; Joshi et al., 2010).”
BackgroundInfluentialFunctional interactions between Stat5 and the glucocorticoid receptor
Stöcklin, E., Wissler, M., Gouilleux, F., & Groner, B. (1996) · Nature · doi:10.1038/383726a0 · Cited by 675 · cited 2×
“Indeed physical and functional interactions between all steroid hormone receptors and Stat5a have been reported (Doppler et al., 2001; Lechner et al., 1997; Stocklin et al., 1996; Stoecklin et al., 1997; Winklehner-Jennewein et al., 1998; Wyszomierski et al., 1999).”
BackgroundID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis
Norton, J. D. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.22.3897 · Cited by 665
Lim, E., Wu, D., Pal, B., Bouras, T., Asselin-Labat, M.-L., Vaillant, F., Yagita, H., Lindeman, G. J., Smyth, G. K., & Visvader, J. E. (2010) · Breast Cancer Research · doi:10.1186/bcr2560 · Cited by 440
Wyszomierski, S. L., Yeh, J., & Rosen, J. M. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.2.0232 · Cited by 124
Nuclear receptor coactivators: structural and functional biochemistry
Bulynko, Y. A., & O’Malley, B. W. (2011) · Biochemistry · doi:10.1021/bi101762x · Cited by 113
Berger, T., Cheung, C. C., Elia, A. J., & Mak, T. W. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000101107 · Cited by 96 · cited 1×
“ERα suppressed expression of the EMT transcription factor Slug and the downstream lipocal in 2 gene that appears to be a major signaling axis driving EMT and invasion/metastasis of breast cancer cells (Berger et al., 2010; Niu et al., 2008; Yang et al., 2009).”
Background
Cited by
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021) · Cancers · doi:10.3390/cancers13174287 · Cited by 1,960
Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer
Kim, J. J., Kurita, T., & Bulun, S. E. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1043 · Cited by 520
Progesterone and Breast Cancer
Trabert, B., Sherman, M. E., Kannan, N., & Stanczyk, F. Z. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz001 · Cited by 271
Légaré, S., & Basik, M. (2016) · Molecular Endocrinology · doi:10.1210/me.2016-1072 · Cited by 63
Metadata
- Authors
- Obr, A. E., & Edwards, D. P.
- Venue
- Molecular and Cellular Endocrinology
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 357
- Issue
- 1-2
- Pages
- 4-17
- ISSN
- 0303-7207 (ISSN-L)
- OpenAlex
- W2032416959
- Cited by
- 189
- References
- 14
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.